Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 2 | 0 | 0 | 0 | 0 |
Analyst Firms Making Recommendations1
- HC Wainwright & Co.
- Alliance Global Partners
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for AcelRx Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/07/2023 | ACRX | Buy Now | AcelRx Pharmaceuticals | $0.76 | 558.07% | HC Wainwright & Co. | Ed Arce | → $5 | Reiterates | Buy → Buy | Get Alert |
| 10/02/2023 | ACRX | Buy Now | AcelRx Pharmaceuticals | $0.76 | 459.36% | Alliance Global Partners | James Molloy | → $4.25 | Initiates | → Buy | Get Alert |
| 09/25/2023 | ACRX | Buy Now | AcelRx Pharmaceuticals | $0.76 | 558.07% | HC Wainwright & Co. | Ed Arce | $8 → $5 | Maintains | Buy | Get Alert |
| 08/18/2023 | ACRX | Buy Now | AcelRx Pharmaceuticals | $0.76 | 952.91% | HC Wainwright & Co. | Ed Arce | → $8 | Upgrade | Neutral → Buy | Get Alert |
| 03/14/2022 | ACRX | Buy Now | AcelRx Pharmaceuticals | $0.76 | — | HC Wainwright & Co. | Ed Arce | — | Downgrade | Buy → Neutral | Get Alert |
| 08/17/2021 | ACRX | Buy Now | AcelRx Pharmaceuticals | $0.76 | 558.07% | HC Wainwright & Co. | Ed Arce | — | Maintains | Buy | Get Alert |
What is the target price for AcelRx Pharmaceuticals (ACRX)?
The latest price target for AcelRx Pharmaceuticals (NASDAQ: ACRX) was reported by HC Wainwright & Co. on December 7, 2023. The analyst firm set a price target for $5.00 expecting ACRX to rise to within 12 months (a possible 558.07% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AcelRx Pharmaceuticals (ACRX)?
The latest analyst rating for AcelRx Pharmaceuticals (NASDAQ: ACRX) was provided by HC Wainwright & Co., and AcelRx Pharmaceuticals reiterated their buy rating.
When is the next analyst rating going to be posted or updated for AcelRx Pharmaceuticals (ACRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AcelRx Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AcelRx Pharmaceuticals was filed on December 7, 2023 so you should expect the next rating to be made available sometime around December 7, 2024.
Is the Analyst Rating AcelRx Pharmaceuticals (ACRX) correct?
While ratings are subjective and will change, the latest AcelRx Pharmaceuticals (ACRX) rating was a reiterated with a price target of $0.00 to $5.00. The current price AcelRx Pharmaceuticals (ACRX) is trading at is $0.76, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.